Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Blood Cancer J ; 9(12): 100, 2019 12 11.
Article in English | MEDLINE | ID: mdl-31827067

ABSTRACT

Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are active monotherapies in the relapsed/refractory setting and their combination (the BBV regimen) possibly enhances their activity. This single-arm multicenter phase 2 study investigated the efficacy and safety of BBV as first salvage therapy in 40 patients with relapsed/refractory HL. Thirty-eight patients were evaluable for efficacy: 30 (78.9%) had a CMR and 2 (5.3%) a partial response, leading to an overall response rate (ORR) of 84.2%. The ORR in the primary refractory subset was 75.0%, among relapsed patients it was 94.4%. Thirty-five patients could mobilize peripheral blood stem cells and 33 underwent ASCT. At a median follow-up of 23 months, the estimated 3-year overall survival and progression-free survival are 88.1% and 67.3%. During therapy, only 3 grade IV cases of neutropenia occurred and resolved within a week. No grade 4 extrahematologic toxicities were reported; skin reactions were however rather frequent (65%). These results suggest that the BBV regimen exhibits promising efficacy and a manageable toxicity in a challenging subpopulation of HL patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bendamustine Hydrochloride , Brentuximab Vedotin , Combined Modality Therapy , Female , Hodgkin Disease/diagnosis , Hodgkin Disease/mortality , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Grading , Salvage Therapy , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
3.
Blood Cancer J ; 6: e425, 2016 05 13.
Article in English | MEDLINE | ID: mdl-27176801

ABSTRACT

An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with (90)Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as long-term follow-up analyses of this combined therapeutic modality are lacking. The overall response rate to the entire regimen was 80%, including 73% (40/55) of complete response (CR) rate and 7% (4/55) of partial response rate. At the time of writing, 24/55 (43.6%) patients experienced a progression disease and 20 of 40 (50%) patients who obtained a CR are still alive in continuous CR. With a median follow-up of 7 years, the disease-free survival was 43.3% and the progression-free survival was 36.1%. The overall survival at 7.9 years was 38.9% (27 deaths mainly because of lymphoma). Two patients developed secondary hematological malignancies, an acute myeloid leukemia and a myelodysplastic syndrome, at 4 and 3 years from radioimmunotherapy, respectively. Our data confirm the feasibility, efficacy and safety of four cycles of R-CHOP followed by radioimmunotherapy consolidation even in the long term: this combination allows dispensing less chemotherapy in a frail group of patients without invalidating response quality and duration.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Large B-Cell, Diffuse/therapy , Yttrium Radioisotopes/therapeutic use , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Murine-Derived/adverse effects , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Combined Modality Therapy , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Female , Follow-Up Studies , Humans , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Prednisone/adverse effects , Prednisone/therapeutic use , Radioimmunotherapy , Rituximab , Survival Analysis , Treatment Outcome , Vincristine/adverse effects , Vincristine/therapeutic use , Yttrium Radioisotopes/administration & dosage
4.
Ann Oncol ; 23(2): 415-20, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21536660

ABSTRACT

BACKGROUND: A prospective, single-arm, open-label, multicenter, nonrandomised phase II trial to evaluate efficacy and safety of short fludarabine, mitoxantrone, and rituximab (FMR) induction followed by radioimmunotherapy, in untreated, intermediate/high-risk follicular non-Hodgkin's lymphoma (NHL) patients. PATIENTS AND METHODS: Fifty-five patients were treated using a sequential treatment schedule of four induction cycles of FMR chemoimmunotherapy, and a subsequent consolidating single administration of (90)Y-ibritumomab tiuxetan ((90)Y-IT), 8-14 weeks later. Patients were eligible for radioimmunotherapy if at least in partial response (PR) after induction, with normal platelet and granulocyte counts and a bone marrow infiltration ≤ 25%. Primary study end points were response rate and hematologic toxic effects; secondary end points were overall survival (OS) and progression-free survival (PFS). RESULTS: All the 55 patients received four induction cycles with an overall response rate of 96% (38 complete responses [CR] and 15 PR). Fifty-one patients (38 in CR and 13 in PR) received (90)Y-IT. By the end of the treatment, 49/55 patients achieved a CR. With a median follow-up of 21 months, the estimated 3-year PFS was 81% and the 3-year OS 100%. CONCLUSIONS: This study has established feasibility, tolerability, and efficacy of a regimen composed by short FMR induction with (90)Y-IT consolidation in untreated intermediate/high-risk follicular NHL patients.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/radiotherapy , Yttrium Radioisotopes/administration & dosage , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Female , Humans , Induction Chemotherapy , Male , Middle Aged , Mitoxantrone/administration & dosage , Prospective Studies , Radioimmunotherapy , Rituximab , Treatment Outcome , Vidarabine/administration & dosage , Vidarabine/analogs & derivatives
5.
Ann Oncol ; 21(6): 1173-1178, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19861578

ABSTRACT

BACKGROUND: Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care but prospective randomized trials are lacking. PATIENTS AND METHODS: We report our monocentric experience in the treatment of seven adult patients with multisystem (MS) LCH (n = 3) or single-system multifocal (SS-m) LCH (n = 4) with the short-course intensive chemotherapy regimen methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomicin (MACOP-B). RESULTS: The overall response rate was 100% [five complete response (CR), two partial response (PR)]. After a median follow-up of 6.5 years, four patients are in first continuous CR and three patients relapsed after 5, 8 and 62 months, respectively. Four patients were evaluated with positron emission tomography (PET) scan: all three PET-negative patients at the end of treatment had a long-lasting response with only one patient relapsing after 5 years. PET scan detected additional bone lesions at diagnosis in two of four patients, changing the treatment program in one of them. CONCLUSIONS: MACOP-B regimen seems to be very active in the treatment of adult MS or SS-m LCH, with long-lasting responses in five of seven patients. PET scan merits further evaluation in the initial staging and in the evaluation of the response to chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Histiocytosis, Langerhans-Cell/drug therapy , Adolescent , Adult , Bleomycin/therapeutic use , Cyclophosphamide/therapeutic use , Disease Progression , Doxorubicin/therapeutic use , Female , Fluorodeoxyglucose F18 , Follow-Up Studies , Histiocytosis, Langerhans-Cell/diagnostic imaging , Humans , Leucovorin/therapeutic use , Male , Methotrexate/therapeutic use , Middle Aged , Positron-Emission Tomography , Prednisone/therapeutic use , Remission Induction , Retrospective Studies , Vincristine/therapeutic use , Young Adult
6.
Ann Oncol ; 21(4): 860-863, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19887465

ABSTRACT

BACKGROUND: Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy. Gemcitabine should be considered a suitable option. We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine. PATIENTS AND METHODS: From May 1997 to September 2007, 39 pretreated MF and PTCLU patients received gemcitabine. Inclusion criteria were as follows: histologic diagnosis of MF or PTCLU; relapsed/refractory disease; age > or =18 years; and World Health Organization performance status of two or less. Nineteen patients had MF and 20 PTCLU. All patients with MF had a T3-T4, N0, and M0 disease and patients with PTCLU had stage III-IV disease. Gemcitabine was given on days 1, 8, and 15 on a 28-day schedule (1200 mg/m(2)/day) for a total of three to six cycles. RESULTS: Overall response rate was 51% (20 of 39 patients); complete response (CR) and partial response (PR) rates were 23% (9 of 39 patients) and 28% (11 of 39 patients), respectively. Patients with MF had a CR rate of 16% and a PR rate of 32% compared with a CR rate of 30% and a PR rate of 25% of PTCLU patients. Among the CR patients, 7 of 9 are in continuous complete response with a variable disease-free interval (15-120 months). CONCLUSION: In our experience, gemcitabine proved to be effective in pretreated MF and PTCLU patients, even in the long term.


Subject(s)
Deoxycytidine/analogs & derivatives , Drug Resistance, Neoplasm , Lymphoma, T-Cell/drug therapy , Adult , Aged , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Chemotherapy, Adjuvant , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Female , Follow-Up Studies , Humans , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/radiotherapy , Male , Middle Aged , Mycosis Fungoides/complications , Mycosis Fungoides/drug therapy , Recurrence , Skin Neoplasms/complications , Skin Neoplasms/drug therapy , Time Factors , Treatment Outcome , Gemcitabine
7.
Mycotoxin Res ; 18(2): 90-6, 2002 Jun.
Article in English | MEDLINE | ID: mdl-23606016

ABSTRACT

Argentina is the first popcorn exporting country worldwide. In 1997-1998 harvest season, 40,000 ha were sown with a production of 125,000 tons; 120,000 tons of this production were exported to more than 40 countries. The objectives of this study were to isolate and to identify the fungi present in this cereal and to assess the occurrence of mycotoxins in freshly harvested popcorn in Buenos Aires province, Argentina, in 1999. All popcorn samples showed fungal contamination. A total of 4,211 isolates were recovered from popcorn kernel samples. The prevalent species isolated wasFusarium verticillioides followed byPenicillium funiculosum, F. graminearum andAlternaria alternata. No aflatoxins, zearalenone, deoxynivalenol or ochratoxin A were detected in the 42 popcorn simples. All samples but one were contaminated with fumonisins (FB) in a range in ug/kg of (not detected-529) for FB1; (not detected-216) for FB2 and (not detected-103) for FB3. Fumonisin contamination levels in Argentinean popcorn were lower than observed in flint corn. No significant differences in fungal and fumonisins contamination levels were observed in the different tested hybrids.

8.
Science ; 292(5515): 267-70, 2001 Apr 13.
Article in English | MEDLINE | ID: mdl-11303098

ABSTRACT

We compared the temporal variability of the heat content of the world ocean, of the global atmosphere, and of components of Earth's cryosphere during the latter half of the 20th century. Each component has increased its heat content (the atmosphere and the ocean) or exhibited melting (the cryosphere). The estimated increase of observed global ocean heat content (over the depth range from 0 to 3000 meters) between the 1950s and 1990s is at least one order of magnitude larger than the increase in heat content of any other component. Simulation results using an atmosphere-ocean general circulation model that includes estimates of the radiative effects of observed temporal variations in greenhouse gases, sulfate aerosols, solar irradiance, and volcanic aerosols over the past century agree with our observation-based estimate of the increase in ocean heat content. The results we present suggest that the observed increase in ocean heat content may largely be due to the increase of anthropogenic gases in Earth's atmosphere.

10.
Science ; 247(4939): 192-5, 1990 Jan 12.
Article in English | MEDLINE | ID: mdl-17813285

ABSTRACT

Simulations from a global climate model with and without orography have been used to investigate the role of mountains in maintaining extensive arid climates in middle latitudes of the Northern Hemisphere. Dry climates similar to those observed were simulated over central Asia and western interior North America in the experiment with mountains, whereas relatively moist climates were simulated in these areas in the absence of orography. The experiments suggest that these interior regions are dry because general subsidence and relatively infrequent storm development occur upstream of orographically induced stationary wave troughs. Downstream of these troughs, precipitation-bearing storms develop frequently in association with strong jet streams. In contrast, both atmospheric circulation and precipitation were more zonally symmetric in the experiment without mountains. In addition, orography reduces the moisture transport into the continental interiors from nearby oceanic sources. The relative soil wetness of these regions in the experiment without mountains is consistent with paleoclimatic evidence of less aridity during the late Tertiary, before substantial uplift of the Rocky Mountains and Tibetan Plateau is believed to have occurred.

SELECTION OF CITATIONS
SEARCH DETAIL
...